Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477477 | 1.00 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL7775794 | 1.00 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3477727 | 0.97 | OPRM1 (0.73) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL29610430 | 0.96 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL22959877 | 0.96 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL10329433 | 0.92 | OPRM1 (0.73) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Myrophine SCHEMBL26043 | 0.89 | OPRD1 (0.56) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Myrophine SCHEMBL29851007 | 0.89 | OPRD1 (0.56) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL22959880 | 0.89 | OPRM1 (0.66) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL2322859 | 0.89 | OPRM1 (0.78) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255502-B1 | DRUG DELIVERY THROUGH SKIN, INTESTINAL, ORAL, NASAL, AND RECTAL MUCOSA ENHANCED BY FORMING INCLUSION COMPLEXES WITH CYCLODEXTRINS (SOLUBILIZERS/STABILIZERS) AND ACID-ADDITION SALTS OF DRUGS (CODEINE) AND A FATTY/BILE ACID | FARMARC NEDERLAND B.V. (NL) | 2001-07-03 | — | — | US | claimed |
| JP-2001508027-A | — | — | 2001-06-19 | — | — | JP | claimed |
| EP-1024833-A1 | Pharmaceutical composition containing acid addition salt of basic drug | FARMARC NEDERLAND B.V. (NL) | 2000-08-09 | — | — | EP | claimed |
| CN-1230123-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-09-29 | — | — | CN | claimed |
| WO-1998002187-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| US-6255502-B1 | DRUG DELIVERY THROUGH SKIN, INTESTINAL, ORAL, NASAL, AND RECTAL MUCOSA ENHANCED BY FORMING INCLUSION COMPLEXES WITH CYCLODEXTRINS (SOLUBILIZERS/STABILIZERS) AND ACID-ADDITION SALTS OF DRUGS (CODEINE) AND A FATTY/BILE ACID | FARMARC NEDERLAND B.V. (NL) | 2001-07-03 | — | — | US | disclosed |
| EP-1024833-A1 | Pharmaceutical composition containing acid addition salt of basic drug | FARMARC NEDERLAND B.V. (NL) | 2000-08-09 | — | — | EP | disclosed |
| CN-1230123-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-09-29 | — | — | CN | disclosed |
| WO-1998002187-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | disclosed |